← All trials
NCT06977308
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2026
- Primary completion
- Oct 1, 2029
- Completion date
- Oct 1, 2030
- First posted
- May 18, 2025
- Last posted
- Oct 30, 2025
- Enrollment
- 115
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- National Institute of Mental Health (NIMH)Collaborator
- Columbia UniversityCollaborator
- Columbia UniversitySponsor investigator
- Stony Brook UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.